Technology
Health
Biotechnology

Vanda Pharmaceuticals

$16.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.70 (4.49%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell VNDA and other stocks, options, ETFs, and crypto commission-free!

About

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Read More Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Employees
270
Headquarters
Washington, District of Columbia
Founded
2002
Market Cap
825.16M
Price-Earnings Ratio
41.52
Dividend Yield
0.00
Average Volume
754.89K
High Today
$16.49
Low Today
$15.65
Open Price
$15.65
Volume
158.97K
52 Week High
$33.44
52 Week Low
$13.67

Collections

Technology
Health
Biotechnology
Medical
US
North America

News

Yahoo FinanceMay 2

Is Vanda Pharmaceuticals Inc. (VNDA) A Good Stock To Buy?

Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings.

267
Seeking AlphaMay 1

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q1 2019 Results - Earnings Call Transcript

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2019 Results Earnings Conference Call May 1, 2019 4:30 AM ET Company Participants Jim Kelly - Executive Vice President, Chief Financial Officer, Treasurer Mihael Polymeropoulos - President and Chief Executive Officer Conference Call Participants Chris Howerton - Jefferies Joel Beatty - Citi Derek Archila - Stifel Esther Rajavelu - Oppenheimer Operator Good day ladies and gentlemen and welcome to the Vanda Pharmaceuticals' first quarter 2019 earnings conf...

87
Yahoo FinanceMay 1

Vanda Pharmaceuticals (VNDA) Q1 Earnings Top Estimates

CRH Medical (CRHM) delivered earnings and revenue surprises of -100.00% and 2.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

35

Earnings

-$0.18
-$0.03
$0.11
$0.26
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.